13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001746382
Total reported value
$47.5M
$47.5M
72 檔
173.3%
During the Q1 2024 filing period, Altium Capital Management LLC (CIK: 0001746382) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $47.5M across 72 reported positions.
During Q1 2024, Altium Capital Management LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | VERA | Vera Therapeutics Inc | Stock-Other | 12.12% | — | +15.45% | |
| 2 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 5.93% | — | +19.78% | |
| 3 | ✓ | Viking Therapeutics Inc | Stock-Other | 5.69% | — | — | |
| 4 | ✓ | Advisorshares Tr | Stock-Other | 4.46% | — | — | |
| 5 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 4.36% | — | — | |
| 6 | ADMA | Adma Biologics Inc | Stock-Healthcare | 4.02% | — | +40.64% | |
| 7 | ✓ | Alimera Sciences Inc | Stock-Other | 3.94% | — | -4.14% | |
| 8 | ✓ | Avadel Pharmaceuticals PLC ADR | Stock-Other | 3.70% | — | — | |
| 9 | XTNT | Xtant Medical Holdings Inc | Stock-Other | 3.54% | — | -4.73% | |
| 10 | CPRX | Catalyst Pharmaceuticals Inc | Stock-Healthcare | 3.15% | — | +29.87% | |
| 11 | ITCIEUR | Intra-cellular Therapies Inc | Stock-Other | 3.09% | — | +59.15% | |
| 12 | BHVN | Biohaven Ltd. | Stock-Other | 3.03% | — | — | |
| 13 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 2.76% | — | — | |
| 14 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 2.71% | — | +46.27% | |
| 15 | SVRA | Savara Inc | Stock-Other | 2.63% | — | +0.15% | |
| 16 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 2.59% | — | +45.75% | |
| 17 | CYBNEUR | Cybin Inc | Stock-Other | 2.28% | — | — | |
| 18 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 2.20% | — | -40.09% | |
| 19 | LRMR | Larimar Therapeutics Inc | Stock-Other | 2.09% | — | — | |
| 20 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 2.07% | — | — | |
| 21 | NGNE | Neurogene Inc | Stock-Other | 2.01% | — | +49.30% | |
| 22 | PRAX | Praxis Precision Medicines I | Stock-Other | 1.89% | — | — | |
| 23 | ACHV | Achieve Life Sciences Inc | Stock-Other | 1.50% | — | — | |
| 24 | ASND | Ascendis Pharma A/S | Stock-Other | 1.50% | — | — | |
| 25 | ✓ | Longboard Pharmaceuticals In | Stock-Other | 1.45% | — | — | |
| 26 | INSM | Insmed Inc | Stock-Healthcare | 1.29% | — | — | |
| 27 | REAL | Realreal Inc/the | Stock-Other | 1.24% | — | — | |
| 28 | NVLSEUR | Alpine Immune Sciences Inc | Stock-Other | 1.22% | — | -1.11% | |
| 29 | BOLD | Boundless Bio Inc | Stock-Other | 1.13% | — | — | |
| 30 | AQST | Aquestive Therapeutics Inc | Stock-Other | 1.12% | — | — | |
| 31 | RYTM | Rhythm Pharmaceuticals Inc | Stock-Other | 0.98% | — | +783.13% | |
| 32 | MIST | Milestone Pharmaceuticals In | Stock-Other | 0.86% | — | — | |
| 33 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 0.79% | — | -80.48% | |
| 34 | ZVRA | Zevra Therapeutics Inc | Stock-Other | 0.78% | — | — | |
| 35 | ✓ | Stock-Other | 0.71% | — | — | ||
| 36 | MRNS* | Marinus Pharmaceuticals Inc | Stock-Other | 0.63% | — | -11.58% | |
| 37 | ✓ | Biovie Inc | Stock-Other | 0.63% | — | — | |
| 38 | TRML | Tourmaline Bio Inc | Stock-Other | 0.59% | — | — | |
| 39 | VERUEUR | Veru Inc | Stock-Other | 0.59% | — | +5.59% | |
| 40 | ✓ | Geron CORP | Stock-Other | 0.52% | — | — | |
| 41 | KPTIEUR | Karyopharm Therapeutics Inc | Stock-Other | 0.44% | — | — | |
| 42 | FATBW | Fat Brands Inc -cw25 | Stock-Other | 0.39% | — | — | |
| 43 | SPRU | Spruce Power Holding Corporation | Stock-Other | 0.36% | — | — | |
| 44 | ISREUR | Isoray Inc | Stock-Other | 0.25% | — | — | |
| 45 | EVOKEUR | Evoke Pharma Inc | Stock-Other | 0.18% | — | — | |
| 46 | PMNT | Perfect Moment LTD | Stock-Other | 0.13% | — | — | |
| 47 | RCKTW | Rocket Pharmaceuticals In-27 | Stock-Other | 0.09% | — | — | |
| 48 | NXGLW | Nexgel Inc -cw26 | Stock-Other | 0.06% | — | — | |
| 49 | ✓ | Mobilicom American Depositary Shares | Stock-Other | 0.06% | — | — | |
| 50 | ✓ | Stock-Other | 0.06% | — | — |
According to official SEC Form 13F filings, Altium Capital Management LLC reported a total U.S. public equity portfolio value of $47.5M across 72 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including VERA, XENE, VIKING THERAPEUTICS INC) accounted for 173.3% of total reported equity market value during Q1 2024.
During Q1 2024, Altium Capital Management LLC's top holdings by market value included VERA (12.1%)、XENE (5.9%)、VIKING THERAPEUTICS INC (5.7%). The largest single position, VERA, represented 12.1% of total portfolio value.
In Q1 2024, Altium Capital Management LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.